Instil BioTIL
About: Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Employees: 14
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
533% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 3
1.61% less ownership
Funds ownership: 81.82% [Q3] → 80.21% (-1.61%) [Q4]
20% less funds holding
Funds holding: 49 [Q3] → 39 (-10) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 3 (-2) [Q4]
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
72% less capital invested
Capital invested by funds: $358M [Q3] → $100M (-$258M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 56 / 186 met price target | 588%upside $110 | Buy Reiterated | 5 Mar 2025 |
Financial journalist opinion









